EVT:ETR
Evotec SE
2,81 EUR
arrow_downward
-1,75%(-0,050) 1 zi
22 oct., 10:56:38 GMT+2 · EUR
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru EVT...
Deschide
2,92 EUR
Mare
2,92 EUR
Mic
2,81 EUR
Capitalizarea bursieră
498,78 mil.
Volum mediu
1,21 mil.
Volum
132,10 K
Prețul ridicat pe 52 de săptămâni
7,30 EUR
Prețul redus pe 52 de săptămâni
2,41 EUR
Rezultatul pe acțiune
-1,11 EUR
Acțiuni aflate în circulație
177,91 mil.
Nr. de angajați
4 K
Deschide
2,92 EUR
Mare
2,92 EUR
Mic
2,81 EUR
Capitalizarea bursieră
498,78 mil.
Volum mediu
1,21 mil.
Volum
132,10 K
Prețul ridicat pe 52 de săptămâni
7,30 EUR
Prețul redus pe 52 de săptămâni
2,41 EUR
Rezultatul pe acțiune
-1,11 EUR
Acțiuni aflate în circulație
177,91 mil.
Nr. de angajați
4 K
Subiecte de știri
Din surse web și de la parteneri de știri
AD HOC NEWS
·
acum 17 ore
Evotec's Nine-Month Beat Meets an Unchanged Loss Forecast — November 5 Is the Real Test
AD HOC NEWS
·
acum 17 ore
Evotec stock: RBC keeps EUR 10.00 target for Evotec stock
AD HOC NEWS
·
acum 1 zi
Evotec appoints Joanna Holbrook as chief scientific officer. Evotec stock gains 1.47 percent
AD HOC NEWS
·
acum 1 zi
Evotec stock at EUR 2.77 ahead of the Xetra open: drug group rises 1.84 percent
Profil
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Despre Evotec SE